FULC 外匯新聞

Biopharmaceutical company Fulcrum Therapeutics, Inc. (FULC) announced Wednesday that Robert Gould, former president and founding chief executive officer, has been appointed as interim CEO, effective January 3, 2023. He is also a current member of the Board of Directors.